利用微流控芯片高效捕获与无痕释放功能性 CD8⁺ T 细胞以增强体外和体内 CD4-CAR 转导

The chimeric antigen receptor (CAR) T cells targeting CD4 expressed cells in acute lymphoblastic leukemia (T-ALL) and acute myeloid leukemia (AML) could reduce the risk of off target effects in normal tissues.

However, the efficacy of adoptive cell therapy is predominantly attributed to CD8 + T cells, necessitating their purification before lentivirus transfection to enhance the production of CD4-CAR-T cells. In this study, we developed a microfluidic chip functionalized with an optimized CD8 aptamer, A3t-MU, to facilitate the enrichment and purification of CD8 + T cells.

The presented chip showed efficient capture and seamless release of CD8 + T cells from cultured T cells and peripheral blood mononuclear cells (PBMCs). The purity of the released CD8 + T cells reached 98. 1%, representing a 13% improvement over the conventional magnetic bead separation method. CD4-CAR was efficiently transduced into the purified CD8 + T cells to construct CAR-T cells.

We evaluated the antitumor capability of the CD4-CAR transduced CD8 + T cells (anti-CD4 CD8-CAR T cells) both in vitro and in vivo . The anti-CD4 CD8-CAR T cells exhibited significant cancer-cell-killing capacity across multiple tumor cell lines, including CEM, Jurkat, and MV4-11. Meanwhile, anti-CD4 CD8-CAR T cells significantly inhibited tumor growth in vivo .

In conclusion, the presented microfluidic chip offers a cost-effective and high-purity approach for CD8 + T cell separation, enhancing CD4-CAR transduction and achieving efficient antitumor capability both in vitro and in vivo .